Solid phase synthesis of benzothiazolyl compounds

[1]  A. Westwell,et al.  The regiospecific synthesis of 5- and 7-monosubstituted and 5,6-disubstituted 2-arylbenzothiazoles† , 2000 .

[2]  E. Sausville,et al.  Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles. , 1999, Journal of medicinal chemistry.

[3]  K. Tsukidate,et al.  Toxicological response of rats to a novel monoamine oxidase type-A inhibitor, (5R)-3-[2-((1S)-3-cyano-1-hydroxypropyl)benzothiazol-6-yl]-5- methoxymethyl-2-oxazolidinone (E2011), orally administered for 13 weeks. , 1999, The Journal of toxicological sciences.

[4]  W. Choi,et al.  Biochemical and pharmacological characteristics of a newly synthesized H+-K+ ATPase inhibitor, YJA20379-1, 2-amino-4,5-dihydro-8-phenylimidazole [2,1-b]thiazolo[5,4-g]benzothiazole , 1999 .

[5]  I. Hall,et al.  Investigations on the Mechanism of Action of the Novel Antitumor Agents 2‐Benzothiazolyl, 2‐Benzoxazolyl, and 2‐Benzimidazolyl Hydrazones Derived from 2‐Acetylpyridine , 1999, Archiv der Pharmazie.

[6]  D. Hadjipavlou-Litina,et al.  Thiazolyl and benzothiazolyl Schiff bases as novel possible lipoxygenase inhibitors and anti inflammatory agents. Synthesis and biological evaluation. , 1998, Drug design and discovery.

[7]  M. Kakiki,et al.  Species differences and mechanism of the epimerization of a new MAO-A inhibitor. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  K. Paull,et al.  2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity. , 1998, British Journal of Cancer.

[9]  M. Soufiaoui,et al.  Nouvelle Voie de Synthèse des 2-Arylbenzothiazoles Transfert d'Electrons Activé par Micro-ondes , 1997 .

[10]  L. Gandía,et al.  'Wide-spectrum Ca2+ channel antagonists': lipophilicity, inhibition, and recovery of secretion in chromaffin cells. , 1997, European journal of pharmacology.

[11]  K. Okamoto,et al.  Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids. , 1997, Journal of medicinal chemistry.

[12]  M. Kakiki,et al.  Absorption, distribution, metabolism and excretion of a new, 14C-labelled oxazolidinone MAO-A inhibitor in rat and dog. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  D. Gatos,et al.  Synthesis of the very acid-sensitive Fmoc-Cys(Mmt)-OH and its application in solid-phase peptide synthesis. , 2009, International journal of peptide and protein research.

[14]  A. Kubota,et al.  E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A. , 1996, The Journal of pharmacology and experimental therapeutics.

[15]  A. Nagel,et al.  Design and synthesis of 1-heteroaryl-3-(1-benzyl-4-piperidinyl)propan-1-one derivatives as potent, selective acetylcholinesterase inhibitors. , 1995, Journal of medicinal chemistry.

[16]  B. Mylari,et al.  Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. , 1991, Journal of medicinal chemistry.

[17]  K. Barlos,et al.  Darstellung geschützter peptid-fragmente unter einsatz substituierter triphenylmethyl-harze , 1989 .

[18]  C. A. Stone,et al.  On the pharmacology of L-645,151: a topically effective ocular hypotensive carbonic anhydrase inhibitor. , 1985, The Journal of pharmacology and experimental therapeutics.

[19]  W. Tucker,et al.  The preparation of some fluorobenzothiasoles , 1965 .